2025 annual financial data
Kymera Therapeutics 2025 Operating margin
Direct answer
Operating margin was -891.33%.
Operating income was -349,400,000 USD and net income was -311,400,000 USD.
Operating cash flow was -232,891,000 USD.
Get free Kymera Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 39,200,000 USD
- Operating income
- -349,400,000 USD
- Net income
- -311,400,000 USD
- Operating cash flow
- -232,891,000 USD